PMC:7696151 / 114593-114959
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 4094 | 95-103 | Species | denotes | patients | Tax:9606 |
| 4147 | 123-126 | Chemical | denotes | HCQ | MESH:D006886 |
| 4209 | 77-85 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 4210 | 86-94 | Disease | denotes | infected | MESH:D007239 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T768 | 0-366 | Sentence | denotes | Abd-Elsalam, et al. (2020) [36] Multicenter, randomized controlled trial194 COVID-19 infected patients HCQ group -> SOC+ HCQ (400 mg twice daily, on day 1, followed by 200 mg tablets twice daily)Control group -> SOC4 weeks of treatment There was no significant difference between the two groups regarding any laboratory parameters or the baseline characteristics. |